Principal Investigators


Professor S Lovestone

Institution


University of Oxford

Contact information of lead PI


Country


United Kingdom

Title of project or programme


WNT signaling: biomarker and target evaluation in Alzheimer's disease

Source of funding information


MRC

Total sum awarded (Euro)


€ 298,443

Start date of award


06/05/2014

Total duration of award in years


2

Keywords


Research Abstract


The consistent failure of biopharmaceutical pipelines to modify Alzheimer’s disease progression indicates a need for new and creative solutions. In this project we will explore elements of the canonical (WNT/GSK3) and non-canonical (WNT/JNK) signaling pathways as novel targets that could be used to monitor and modify Alzheimer’s progression. Our teams are applying a multidisciplinary approach that combines brain-oriented drug screening, new genetic and pharmacological tools, new animal models and human blood and cerebrospinal fluid samples, which, together, explore the impact on AD of novel WNT elements, including but not limited to the apolipoprotein clusterin, the WNT inhibitor DKK1 and the transcription factor Nrf2.

Further information available at:

Export as PDF